1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Basilea Says Phase II Derazantinib Data Keep Drug’s Prospects On Track

 
• By Sten Stovall

Basilea reported positive interim results from its registrational Phase II study with oncology drug candidate derazantinib in intrahepatic cholangiocarcinoma, or bile duct cancer.

Internal organs
Derazantinib Is In Phase II Testing For Intrahepatic Bile Duct Cancer • Source: Shutterstock

Promising efficacy and safety tolerability shown by derazantinib in an interim analysis of its Phase II registrational study in bile duct cancer has reinforced Basilea Pharmaceutica Ltd. hopes of extending the clinical development program of the pan-fibroblast growth factor receptor inhibitor in other types of FGFR-driven solid tumors, the company said.

Derazantinib (BAL087, formerly ARQ 087) is a Phase III fibroblast growth factor receptor antagonist for intrahepatic cholangiocarcinoma (iCCA), a disease...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Clinical Trials

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By Kevin Grogan

Lynkuet will compete with Astellas's Veozah/Veoza

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

More from R&D

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By Kevin Grogan

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Lupin’s Cimzia Biosimilar Candidate Reflects Strategy To Separate Wheat From Chaff

 
• By Vibha Ravi

Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers